190.28
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$190.83
Offen:
$191.4
24-Stunden-Volumen:
3.78M
Relative Volume:
0.59
Marktkapitalisierung:
$336.11B
Einnahmen:
$57.37B
Nettoeinkommen (Verlust:
$4.20B
KGV:
80.97
EPS:
2.35
Netto-Cashflow:
$15.39B
1W Leistung:
+0.54%
1M Leistung:
+2.64%
6M Leistung:
+11.73%
1J Leistung:
+4.45%
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ABBV
Abbvie Inc
|
190.28 | 337.08B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
LLY
Lilly Eli Co
|
812.69 | 723.06B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
168.30 | 407.97B | 90.63B | 22.66B | 16.40B | 9.35 |
![]()
NVS
Novartis Ag Adr
|
117.70 | 227.39B | 55.19B | 13.65B | 16.81B | 6.86 |
![]()
NVO
Novo Nordisk Adr
|
71.70 | 314.28B | 43.59B | 15.04B | 10.74B | 3.3766 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
2024-11-04 | Hochstufung | Argus | Hold → Buy |
2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
2023-10-20 | Fortgesetzt | UBS | Neutral |
2023-09-29 | Eingeleitet | Raymond James | Outperform |
2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-04-05 | Herabstufung | Argus | Buy → Hold |
2023-03-01 | Eingeleitet | Guggenheim | Buy |
2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
2022-02-28 | Herabstufung | UBS | Buy → Neutral |
2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
2022-02-03 | Bestätigt | Barclays | Equal Weight |
2022-02-03 | Bestätigt | BofA Securities | Neutral |
2022-02-03 | Bestätigt | Goldman | Neutral |
2022-01-13 | Eingeleitet | Redburn | Buy |
2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
2021-07-27 | Fortgesetzt | Truist | Buy |
2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
2020-11-10 | Fortgesetzt | Bernstein | Outperform |
2020-09-29 | Eingeleitet | Berenberg | Hold |
2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
2020-06-02 | Hochstufung | Argus | Hold → Buy |
2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
2020-02-27 | Eingeleitet | Barclays | Equal Weight |
2020-02-06 | Eingeleitet | Mizuho | Buy |
2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2019-12-26 | Bestätigt | Cowen | Outperform |
2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2019-05-28 | Eingeleitet | Goldman | Neutral |
2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Why AbbVie (ABBV) Is a High-Conviction Buy Despite Mixed Analyst Sentiment - AInvest
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT - Insider Monkey
AbbVie (ABBV) Positioned for Growth With Strong Skyrizi, Rinvoq Sales, Says JPMorgan - Insider Monkey
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever. - The Motley Fool
What catalysts could drive AbbVie Inc. stock higher in 2025Consistent high-yield stocks - jammulinksnews.com
AbbVie’s Phase 3 Study on Telisotuzumab Vedotin: A Potential Game-Changer in NSCLC Treatment - The Globe and Mail
What analysts say about AbbVie Inc. stockGame-changing returns - PrintWeekIndia
Is AbbVie Inc. a good long term investmentExplosive portfolio gains - PrintWeekIndia
AbbVie’s Phase 3 Study on Upadacitinib for SLE: A Potential Game Changer? - The Globe and Mail
AbbVie’s Latest Clinical Study on Glaucoma Gel Stent: Market Implications - The Globe and Mail
What drives AbbVie Inc. stock priceExceptional portfolio growth - PrintWeekIndia
MHRA approves AbbVie’s Elahere - The Pharma Letter
AbbVie’s Pediatric Atopic Dermatitis Study: A Potential Game-Changer? - TipRanks
AbbVie’s Long-term Study on Bimatoprost SR: Market Implications and Study Insights - TipRanks
September 5th Options Now Available For AbbVie (ABBV) - Nasdaq
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
The 3 Things That Matter for AbbVie Now - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Staar Surgical (STAA) and Universal Health (UHS) - The Globe and Mail
Endometriosis Drugs Market Growing at Robust Expansion of the Decade: AbbVie, Pfizer, Astellas Pharma - openPR.com
Final Trades: Abbvie, Uber, Western Union and Live Nation - CNBC
Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports - Yahoo Finance
AbbVie (ABBV) Outperforms Broader Market: What You Need to Know - Yahoo Finance
AbbVie Inc. Stock Analysis and ForecastBreakthrough profits - jammulinksnews.com
Lip Fillers Market Is Booming So Rapidly 2025-2032Allergan (AbbVie Inc.), Galderma S.A., Merz Pharma - openPR.com
Why AbbVie (ABBV) is a Strong Buy for Diversified Portfolios in a Volatile Market - AInvest
4 Reasons To Buy AbbVie (NYSE:ABBV) - Seeking Alpha
How Will AbbVie's Neuroscience Franchise Perform In Q2 Earnings? - Barchart.com
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings? - Yahoo Finance
IGI, Abbvie team up to advance myeloma treatment ISB 2001 - Rare Cancer News
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project - AbbVie News Center
BOTOX Invests $400,000 in Women Entrepreneurs Through Elite 12-Week Business Accelerator Program - Stock Titan
Lobbying Update: $1,160,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
AbbVie's Allergan wins $56 million in Botox patent fight - Crain's Chicago Business
AbbVie unit wins $56 mln in US patent trial against Botox rival - Reuters
AbbVie Unit Wins $56 Million from Revance Over Botox Patents (1) - Bloomberg Law News
Stacey McCullough: I’m Thrilled to Join AbbVie Oncology Working in Market Access - Oncodaily
Non-Small Cell Lung Cancer Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca - Barchart.com
AbbVie’s Promising Phase 2 Study on ADPKD Treatment: What Investors Need to Know - The Globe and Mail
AbbVie's Q1 2025 Earnings Surge 6.5% Year-Over-Year - AInvest
AbbVie Stock (ABBV) Opinions on Recent Price Surge and Sales Growth - Quiver Quantitative
Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT - MSN
AbbVie’s Phase 3 Study on Atogepant: A Potential Game-Changer for Pediatric Migraine Prevention - TipRanks
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):